
INTS Stock Forecast & Price Target
INTS Analyst Ratings
Bulls say
Intensity Therapeutics is viewed favorably because its lead intratumoral candidate INT230-6 is advancing in two key studies, with INVINCIBLE-3 restarting enrollment in 2026 and INVINCIBLE-4 showing early encouraging signals in early-stage, operable TNBC. The first 14 patients showed a 71% pCR rate in Cohort A versus 42% in Cohort B, plus a 44% reduction in grade 3 adverse events and fewer immune-related adverse events, supporting both efficacy and tolerability. Although 3Q26 brought a net loss of $3.5 million on $2.4 million of R&D and $1.2 million of G&A, the company still has clinical momentum and enough progress to justify a positive fundamental outlook despite dilution concerns.
Bears say
Intensity Therapeutics is a late-stage clinical biotechnology company whose outlook is pressured by substantial regulatory risk, including FDA and international agency scrutiny, as well as the possibility that standard-setting organizations could slow or complicate development and commercialization. Its reliance on a single intratumoral platform and product candidate, INT230-6, also heightens execution risk, because any setback in clinical validation, manufacturing, or adoption could materially weaken the investment case. Fundamentally, the company’s lack of profitability and liquidity issues are especially concerning for a biotech with no stated commercial base, while larger competitors may have greater resources to advance similar oncology approaches more quickly.
This aggregate rating is based on analysts' research of Intensity Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
INTS Analyst Forecast & Price Prediction
Start investing in INTS
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Intensity Therapeutics Inc (INTS) Forecast
INTS Analyst Forecast & Price Prediction
Start investing in INTS
Order type
Buy in
Order amount
Est. shares
0 shares